BHCM
IRWD icon

Brevan Howard Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Brevan Howard Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,218
Closed -$49.9K – 2317
2026
Q1 		$49.9K Buy
+14,218
New +$58.3K ﹤0.01% 2087
2025
Q2 		– Sell
-34,658
Closed -$50.9K – 1922
2025
Q1 		$50.9K Buy
+34,658
New +$82.5K ﹤0.01% 1089
2024
Q3 		– Sell
-68,200
Closed -$445K – 1290
2024
Q2 		$445K Buy
68,200
+39,226
+135% +$277K ﹤0.01% 653
2024
Q1 		$252K Sell
28,974
-19,654
-40% -$238K ﹤0.01% 722
2023
Q4 		$556K Buy
48,628
+34,030
+233% +$337K 0.01% 435
2023
Q3 		$141K Buy
+14,598
New +$143K ﹤0.01% 342

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brevan Howard Capital Management's IRWD Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 14,218 shares — an estimated $49.9K sold.

Brevan Howard Capital Management first reported a position in IRWD in Q3 2023 and held it in 6 quarters. The position peaked at $556K in Q4 2023. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 14,218 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $49.9K.
  • Brevan Howard Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • Brevan Howard Capital Management's Ironwood Pharmaceuticals position peaked at $556K in Q4 2023.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.